Epidemiological study of respiratory syncytial virus infection in adults during the pandemic of COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9608375 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7780 (Electronic) Linking ISSN: 1341321X NLM ISO Abbreviation: J Infect Chemother Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Amsterdam : Elsevier
      Original Publication: Tokyo : New York : Published for the Society by Churchill Livingstone, c1995-
    • Subject Terms:
      Respiratory Syncytial Virus Infections*/epidemiology ; Respiratory Syncytial Virus Infections*/virology ; COVID-19*/epidemiology ; COVID-19*/virology ; SARS-CoV-2*; Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Japan/epidemiology ; Aged ; Adult ; Respiratory Syncytial Virus, Human/isolation & purification ; Influenza, Human/epidemiology ; Influenza, Human/virology ; Aged, 80 and over ; Comorbidity ; Pandemics ; Influenza A virus/isolation & purification ; Influenza A virus/genetics ; Respiratory Tract Infections/epidemiology ; Respiratory Tract Infections/virology
    • Abstract:
      Introduction: While respiratory syncytial virus (RSV) is one of the most common pathogens in adults admitted to the ICU due to respiratory diseases, no reports regarding the occurrence rate of RSV infections in adults in Japan during the COVID-19 pandemic exist.
      Patients and Methods: We conducted this retrospective study to examine the exact occurrence rate of RSV infections in adults. We reviewed all patients (≥18 years) with any respiratory symptoms who received quantitative polymerase chain reaction (PCR) using nasopharyngeal samples for respiratory viruses by GeneLEAD at the Aichi Medical University Hospital between November 2022 and November 2023.
      Results: A total of 541 adult patients who underwent PCR test were enrolled in this study. RSV was identified in 18 cases (3.3 %); 8 (1.5 %) upper and 10 (1.8 %) lower respiratory tract infections. Influenza A and SARS-CoV-2 were found in 10 (1.8 %) and 61 (11.3 %), respectively. Patients with RSV infections and COVID-19 had more comorbidities than those with Influenza virus infections. As for RSV-associated with lower respiratory tract infection cases, 10 developed acute respiratory failure, resulting in 1 fatal case due to pneumonia and 1 died of septic shock due to ileus. The 30-, 90-day mortality rates were 1 (6 %) and 2 (11 %) respectively.
      Conclusion: About 3 % of adults had RSV infections during the COVID-19 pandemic. The outcomes of RSV infections in adults were similar to those by COVID-19. Those with comorbidities should have a preventive method against RSV infections, the same as for COVID-19.
      Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest.
      (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: COVID-19; GeneLEAD; Pandemic; Respiratory syncytial virus
    • Publication Date:
      Date Created: 20240523 Date Completed: 20240911 Latest Revision: 20240911
    • Publication Date:
      20240912
    • Accession Number:
      10.1016/j.jiac.2024.05.004
    • Accession Number:
      38782237